Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice

Journal of Crohn's and Colitis

Volumn 10, Issue 4, 2016, Pages 402-409

  Vivio, Emily E ^a   Kanuri, Navya ^a   Gilbertsen, Joanna J ^a   Monroe, Kelly ^a   Dey, Neelendu ^a   Chen, Chien Huan ^a   Gutierrez, Alexandra M ^a   Ciorba, Matthew A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical practice; Entyvio; MAdCAM; Vedolizumab

Indexed keywords

ADALIMUMAB; ADRENALIN; AMPHOTERICIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; METHOTREXATE; NATALIZUMAB; VEDOLIZUMAB; VORICONAZOLE; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ANAPHYLAXIS; ARTICLE; BASAL CELL CARCINOMA; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COLITIS; COLON RESECTION; CONJUNCTIVITIS; CONTROLLED STUDY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYTOMEGALOVIRUS INFECTION; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FEVER; HARVEY BRADSHAW INDEX; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; INFLAMMATORY BOWEL DISEASE; INFORMED CONSENT; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAYO SCORE; PRIORITY JOURNAL; QUALITY OF LIFE ASSESSMENT; RASH; RETROSPECTIVE STUDY; TREATMENT DURATION; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84966283916     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jjv226     Document Type: Article

References (21)

1. Danese S, Vuitton L, Peyrin-Biroulet L. Biologic agents for IBD: practical insights. Nat Rev Gastroenterol Hepatol 2015;12:537-45.
2. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83.
3. Chen CH, Kularatna G, Stone CD, Gutierrez AM, Dassopoulos T. Clinical experience of natalizumab in Crohn's disease patients in a restricted distribution program. Ann Gastroenterol 2013;26:189-90.
4. Juillerat P, Wasan SK, Fowler SA, et al. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis 2013;19:2457-63.
5. Sakuraba A, Keyashian K, Correia C, et al. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis 2013;19:621-6.
6. Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology 2014;147:618-27.e3.
7. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
8. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
9. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:9A-13A.
10. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-44.
11. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
12. Henao MP, Bewtra M, Osterman MT, et al. Measurement of inflammatory bowel disease symptoms: reliability of an abbreviated approach to data collection. Inflamm Bowel Dis 2015;21:2262-71.
13. Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008;14:1660-6.
14. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 2012;159:313-25.
15. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-8.
16. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SESCD. Gastrointest Endosc 2004;60:505-12.
17. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9.
18. Shelton E, Allegretti JR, Stevens B, et al. Efficacy of vedolizumab as induction therapy in refractory IBD patients: a multicenter cohort. Inflamm Bowel Dis 2015; 21:2879-85.
19. Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 2012;10:1002-7; quiz e78.
20. Hagan M, Cross RK. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2015;14:1473-9.
21. Bryant RV, Sandborn WJ, Travis SP. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis 2015;9:356-66.